
...

By Lucy Notarantonio
Senior Reporter
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
Alzheimer’s disease affects millions worldwide—but confirming a diagnosis is far from simple. Doctors currently rely on costly brain scans or invasive spinal fluid tests to identify the condition—methods that can be stressful, time-consuming and out of reach for many patients.
Now, researchers say a simpler approach could be on the horizon: just a quick prick of a patient’s fingertip might one day help doctors detect the disease, which affects an estimated 7.2 million Americans age 65 and older.
Neuroscientist Nicholas Ashton of the University of Gothenburg, Sweden, and colleagues tested a new method for detecting Alzheimer’s disease using a few drops of blood obtained from the fingertip and then dried on a card.
Read More on Health
Ashton told Newsweek: "We now have FDA-approved blood tests that can support the diagnostic evaluation of Alzheimer’s disease, and these tools are becoming increasingly commonplace. Their use has the potential to reduce diagnostic waiting times and significantly enhance individualized patient management."

...
How the Finger-Prick Test Works
In the study of 337 people, the researcher measured proteins linked to Alzheimer’s—including a key marker called p-tau217—and found that the results of their finger-prick tests closely matched those from standard blood tests. The method was able to detect Alzheimer’s-related changes in spinal fluid with about 86 percent accuracy.
Two other markers also showed strong agreement: GFAP, a protein released when brain support cells are stressed, and NfL, fragments from damaged nerve cells—both of which act as warning signals of brain changes.
Participants were able to collect their own samples without help from medical staff—a breakthrough that could make testing accessible in remote areas or for people who face higher risks, such as those with Down Syndrome.
The team caution that the technique is not ready for clinical use yet. More research is needed before it becomes a routine tool.
Ashton said: "Remote blood-based testing has the potential to substantially advance this effort by enabling broader, more inclusive participation in research worldwide."
But if successful, this simple test could pave the way for large-scale studies and easier screening worldwide—offering hope for earlier detection and improved quality of life for millions.
According to the Alzheimer’s Association, the brain disorder begins 20 years or more before memory loss and
other symptoms develop. Nearly three-quarters of people living with it are age 75 or older.
The Fisher Center for Alzheimer’s Research Foundation reports it takes an average of three-and-a-half years after symptoms are first noticed for people with Alzheimer’s or other forms of dementia to receive confirmation.
Early Detection and Diagnosis: Why It Matters
Ashton told Newsweek: "The field is increasingly focused on diagnosing and treating Alzheimer’s disease at earlier stages. Ongoing clinical trials are evaluating interventions in individuals who are asymptomatic but have pathological evidence of Alzheimer’s disease.
"If these approaches are shown to be effective and meaningful, a remote triage test—such as the one described here—would be of considerable value. Many of these individuals would not otherwise present to primary care or specialized memory clinics, as they do not yet experience cognitive symptoms."
Identifying Alzheimer’s early can do more than open doors to treatment; it can improve quality of life by:
- Reducing anxiety and providing clarity.
- Empowering informed decisions and a sense of control.
- Supporting financial and care planning with family.
- Encouraging healthy habits like exercise and good nutrition.
- Prompting safety measures for driving, medications, and home adjustments.
- Improving outcomes through earlier intervention.
Update 01/08/26, 03:40 a.m. ET: This story has been updated to add comments from Nicholas Ashton.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about Alzheimer's disease? Let us know via health@newsweek.com.
Reference
Huber, H., Montoliu-Gaya, L., Brum, W. S., Vávra, J., Yakoub, Y., Weninger, H., Braun-Wohlfahrt, L. S., Simrén, J., Boada, M., Ruiz, A., & Ashton, N. J. (2026). A minimally invasive dried blood spot biomarker test for the detection of Alzheimer’s disease pathology. Nature Medicine. https://doi.org/10.1038/s41591-025-04080-0
View 0 Comments
Submit Correction
View Editorial & AI Guidelines